{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:26Z","timestamp":1787844206499,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The aim of this article is to assess the outcomes of a low-intensity extracorporeal shock wave therapy (LiESWT) protocol for the treatment of Peyronie's disease (PD). Patients treated for PD were prospectively recorded, and data were retrospectively reviewed. Age, characteristics of fibrous plaques, concomitant treatments, International Index of Erectile Function (IIEF-5), Lue score, and pain score on Likert scale were collected. Patients in acute phase of PD and an angulation of &lt;40\u00b0 were included. The protocol consisted of 6 weekly sessions of 4000 pulses each, applied from different directions, with a maximal power of 20 W and 8 Hz frequency. We included 39 patients (median age: 56.8 years, interquartile range [IQR]: 35.8\u201362.2 years). The median number of sessions received per patient was 7.2. After treatment, the median Lue score decreased from 6.8 initially to 3.3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003), the median Likert pain score dropped from 1.8 to 0.7 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004), the median plaque size was reduced from 2 cm to 1.2 cm (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.08), and the median penile curvature diminished from 31\u00b0 to 17\u00b0 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.07). On univariate and multivariate analysis, the only predictors of success were younger age (odds ratio [OR] = 0.95,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03 and OR = 0.91,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04, respectively) and concomitant use of phosphodiesterase-5 inhibitors (PDE5i; OR = 0.92,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02 and OR = 0.93,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01, respectively). LiESWT had a favorable impact on Lue score and notably penile pain, curvature, plaque size, and erectile function in patients treated for PD during the early inflammatory phase, with no side effects. Younger age and concomitant use of PDE5i were the only success predictors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aja.aja_40_21","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T07:26:02Z","timestamp":1621668362000},"page":"45-49","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Low-intensity extracorporeal shock wave therapy for Peyronie's disease"],"prefix":"10.4103","volume":"24","author":[{"given":"Maher","family":"Abdessater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Akakpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kanbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Chartier-Kastler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240829","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.urology.2015.03.010","article-title":"Intralesional injections for early Peyronie disease: standardized assessment and analysis of predictive factors for treatment response","volume":"86","author":"Wolff","year":"2015","journal-title":"Urology"},{"key":"R2-8-20240829","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.sxmr.2019.12.002","article-title":"Noninvasive treatment options for Peyronie's disease","volume":"8","author":"Ory","year":"2020","journal-title":"Sex Med Rev"},{"key":"R3-8-20240829","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.purol.2020.03.002","article-title":"[Non-surgical management of Peyronie's disease: state of current knowledge]","volume":"30","author":"Abdessater","year":"2020","journal-title":"Prog Urol"},{"key":"R4-8-20240829","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.02.033","article-title":"Shock wave technology and application: an update","volume":"59","author":"Rassweiler","year":"2011","journal-title":"Eur Urol"},{"key":"R5-8-20240829","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrm2594","article-title":"Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus","volume":"10","author":"Wang","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R6-8-20240829","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1464-410X.2000.00827.x","article-title":"Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience","volume":"86","author":"Husain","year":"2000","journal-title":"BJU Int"},{"key":"R7-8-20240829","doi-asserted-by":"crossref","first-page":"366","DOI":"10.21037\/tau.2016.03.26","article-title":"Pro: does shockwave therapy have a place in the treatment of Peyronie's disease?","volume":"5","author":"Chung","year":"2016","journal-title":"Transl Androl Urol"},{"key":"R8-8-20240829","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jsxm.2019.12.024","article-title":"The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial","volume":"17","author":"Baccaglini","year":"2020","journal-title":"J Sex Med"},{"key":"R9-8-20240829","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/01.ju.0000108060.30363.8d","article-title":"Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials","volume":"171","author":"Hauck","year":"2004","journal-title":"J Urol"},{"key":"R10-8-20240829","doi-asserted-by":"crossref","first-page":"775","DOI":"10.4111\/kju.2015.56.11.775","article-title":"Peyronie's disease and low intensity shock wave therapy: clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men","volume":"56","author":"Chung","year":"2015","journal-title":"Korean J Urol"},{"key":"R11-8-20240829","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"R12-8-20240829","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1743-6109.2004.10104.x","article-title":"Summary of the recommendations on sexual dysfunctions in men","volume":"1","author":"Lue","year":"2004","journal-title":"J Sex Med"},{"key":"R13-8-20240829","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill pain questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"key":"R15-8-20240829","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","article-title":"Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial","volume":"106","author":"Chitale","year":"2010","journal-title":"BJU Int"},{"key":"R16-8-20240829","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","article-title":"Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial","volume":"35","author":"Palmieri","year":"2012","journal-title":"Int J Androl"},{"key":"R17-8-20240829","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","article-title":"A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease","volume":"56","author":"Palmieri","year":"2009","journal-title":"Eur Urol"},{"key":"R18-8-20240829","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.sxmr.2019.02.001","article-title":"Shockwave therapy in the treatment of Peyronie's disease","volume":"7","author":"Krieger","year":"2019","journal-title":"Sex Med Rev"},{"key":"R19-8-20240829","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ijir.2016.24","article-title":"A meta-analysis of extracorporeal shock wave therapy for Peyronie's disease","volume":"28","author":"Gao","year":"2016","journal-title":"Int J Impot Res"},{"key":"R20-8-20240829","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1111\/jsm.12275","article-title":"Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study","volume":"10","author":"Hatzichristodoulou","year":"2013","journal-title":"J Sex Med"},{"key":"R21-8-20240829","first-page":"252","article-title":"Effect of high energy shock waves on bony tissue","volume":"16","author":"Graff","year":"1988","journal-title":"Urol Res"},{"key":"R22-8-20240829","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/end.1999.13.549","article-title":"Treatment of Peyronie's disease by extracorporeal shockwave therapy: evaluation of our preliminary results","volume":"13","author":"Abdel-Salam","year":"1999","journal-title":"J Endourol"},{"key":"R23-8-20240829","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.esxm.2019.11.002","article-title":"Prevalence, risk factors, and erectile dysfunction associated with Peyronie's disease among men seeking urological care","volume":"8","author":"Segundo","year":"2020","journal-title":"Sex Med"},{"key":"R24-8-20240829","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1109\/ULTSYM.1989.67136","article-title":"Biological effects of extracorporeal shock waves","volume":"2","author":"Delius","year":"1989","journal-title":"Proc IEEE Ultrason Symp"},{"key":"R25-8-20240829","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1464-410x.2001.02194.x","article-title":"Peyronie's disease - the Plymouth experience of extracorporeal shockwave treatment","volume":"87","author":"Hamm","year":"2001","journal-title":"BJU Int"},{"key":"R26-8-20240829","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0090-4295(02)01970-2","article-title":"Evaluation of extracorporeal shock wave therapy in Peyronie's disease","volume":"60","author":"Manikandan","year":"2002","journal-title":"Urology"},{"key":"R27-8-20240829","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.physio.2014.06.004","article-title":"Relative utility of a visual analogue scale vs. a six-point Likert scale in the measurement of global subject outcome in patients with low back pain receiving physiotherapy","volume":"101","author":"Harland","year":"2015","journal-title":"Physiotherapy"},{"key":"R28-8-20240829","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1063-4584(03)00082-7","article-title":"Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement","volume":"11","author":"Bolognese","year":"2003","journal-title":"Osteoarthritis Cartilage"},{"key":"R29-8-20240829","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4103\/0974-7796.192100","article-title":"Role of extracorporeal shock wave therapy in management of Peyronie's disease: a preliminary report","volume":"8","author":"Shimpi","year":"2016","journal-title":"Urol Ann"},{"key":"R30-8-20240829","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.21037\/tau-20-796","article-title":"Diagnosis of hypogonadism in patients treated with low energy shock wave therapy for erectile dysfunction: a narrative review","volume":"9","author":"Ka\u0142ka","year":"2020","journal-title":"Transl Androl Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_40_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:14:25Z","timestamp":1787843665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_40_21"}},"subtitle":["a single-center experience"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/aja.aja_40_21","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}